USC.edu
Are You a Patient?

Deepa Bhojwani, MBBS, DCH

Professor of Pediatrics (Clinical Scholar)

Image of Deepa Bhojwani, MBBS, DCH
Is this your profile? Click to edit
Email [email protected]
CTSI Profile

Publications

  • Children’s Oncology Group blueprint for research: Acute lymphoblastic leukemia. Pediatr Blood Cancer. 2023 09; 70.. View in PubMed
  • Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure. Transplant Cell Ther. 2023 09; 29(9):574.e1-574.e10.. View in PubMed
  • Efficacy and safety of FLAG-IDA as front-line therapy in de novo paediatric acute myeloid leukaemia population. Br J Haematol. 2023 07; 202(1):e3-e6.. View in PubMed
  • Artemis inhibition as a therapeutic strategy for acute lymphoblastic leukemia. Front Cell Dev Biol. 2023; 11:1134121.. View in PubMed
  • Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells. Blood Adv. 2023 02 28; 7(4):575-585.. View in PubMed
  • Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial. Blood Adv. 2023 02 28; 7(4):602-610.. View in PubMed
  • Patients with Down syndrome can be included in early phase clinical trials- a report from the T2016-003 Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) study. Leukemia. 2023 05; 37(5):1138-1140.. View in PubMed
  • Asparaginase toxicity in Hispanic adult and pediatric patients with acute lymphoblastic leukemia: current understanding. Expert Opin Drug Metab Toxicol. 2023 Jan-Jun; 19(6):357-366.. View in PubMed
  • Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy. Blood Adv. 2022 09 13; 6(17):5222-5226.. View in PubMed
  • Real-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium. Pediatr Blood Cancer. 2022 10; 69(10):e29812.. View in PubMed

Similar People